Overview
Hodgkin lymphoma, lymphocyte-rich (LRHL) is a subtype of classical Hodgkin lymphoma characterized by a predominance of lymphocytes in the background infiltrate surrounding the characteristic Hodgkin Reed-Sternberg (HRS) cells. This subtype is clinically significant due to its distinct biological behavior compared to other forms of Hodgkin lymphoma, often presenting with a more indolent course and better prognosis. LRHL predominantly affects young adults but can occur across all age groups. Accurate diagnosis and tailored management are crucial in day-to-day practice to optimize patient outcomes and minimize treatment-related toxicities 1.Pathophysiology
The pathophysiology of Hodgkin lymphoma, lymphocyte-rich, revolves around the malignant transformation of B lymphocytes into HRS cells, which are hallmark cells in Hodgkin lymphoma. These HRS cells are typically large, multinucleated, and express CD30 and CD15, distinguishing them from normal lymphocytes. The lymphocyte-rich environment suggests a more robust immune response within the tumor microenvironment, potentially contributing to the relatively favorable prognosis observed in LRHL compared to other subtypes 1. Molecularly, genetic alterations such as chromosomal translocations involving the BCL2 gene can play a role, although specific drivers in LRHL are less extensively characterized compared to other lymphomas. The interplay between HRS cells and the surrounding immune cells, including T cells and various lymphocyte subsets, likely influences disease progression and response to therapy 1.Epidemiology
The incidence of Hodgkin lymphoma, including the lymphocyte-rich subtype, has shown a gradual decline over recent decades, though precise figures for LRHL specifically are limited. Generally, Hodgkin lymphoma affects individuals predominantly in their late teens to early adulthood, with a slight male predominance. Geographic variations exist, with higher incidences reported in certain regions, possibly influenced by environmental and genetic factors. Risk factors include a history of infectious mononucleosis and certain familial predispositions, though these associations are not as robustly documented for LRHL compared to other subtypes 1.Clinical Presentation
Patients with Hodgkin lymphoma, lymphocyte-rich, typically present with painless lymphadenopathy, often localized initially but potentially progressing to involve multiple lymph node regions. Common sites include cervical, axillary, and mediastinal lymph nodes. Systemic symptoms such as fever, night sweats, and weight loss (B symptoms) may be present but are less frequent compared to other subtypes. Constitutional symptoms can signal disease progression or transformation. Rarely, extranodal involvement can occur, affecting organs like the liver, spleen, or bone marrow, which may present with more specific symptoms related to organ dysfunction. Early recognition of these presentations is crucial for timely intervention 1.Diagnosis
The diagnosis of Hodgkin lymphoma, lymphocyte-rich, involves a comprehensive approach combining clinical evaluation, imaging, and histopathological examination. Key diagnostic criteria include:Biopsy Confirmation: Core needle biopsy or excisional biopsy of affected lymph nodes is essential. Histopathological examination must identify characteristic HRS cells surrounded by a lymphocyte-rich infiltrate 1.
Immunophenotyping: Immunohistochemical staining is critical to confirm HRS cell markers such as CD30 and CD15 positivity, while also assessing the background lymphocyte profile 1.
Imaging Studies: CT scans or PET-CT scans help assess the extent of disease and guide staging. These imaging modalities are crucial for determining the presence of bulky disease or extranodal involvement 1.
Laboratory Tests: While not diagnostic, complete blood count (CBC) parameters like elevated neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) can reflect systemic inflammation associated with lymphoma 1.Differential Diagnosis:
Lymphadenitis: Often presents with localized symptoms and responds to antibiotics if infectious.
Non-Hodgkin Lymphomas: Distinguishable by the absence of HRS cells and different immunophenotypic profiles.
Metastatic Disease: Clinical context and imaging characteristics help differentiate, particularly in older patients 1.Management
First-Line Treatment
Chemotherapy Regimens: ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine) is a standard first-line approach, offering high efficacy with manageable toxicity profiles 1.
- Adriamycin: 25 mg/m2 IV on days 1, 8, 15, 22
- Bleomycin: 10 mg IV on days 1, 8, 15, 22
- Vinblastine: 6 mg IV on days 1, 8, 15, 22
- Dacarbazine: 375 mg/m2 IV on days 1, 15
- Duration: Typically 6 cycles over 6-8 weeks 1.
Monitoring: Regular CBC, renal function tests, and pulmonary function assessments to monitor for treatment-related toxicities 1.Second-Line Treatment
Refractory or Relapsed Disease: Options include escalated chemotherapy regimens like BEACOPP (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone) or targeted therapies such as brentuximab vedotin.
- Brentuximab Vedotin: 1.8 mg/kg IV every 3 weeks until progression or unacceptable toxicity 1.
Consolidation/Radiation Therapy: Post-chemotherapy radiation therapy may be considered for residual masses or bulky disease 1.Contraindications
Bleomycin: Contraindicated in patients with significant pulmonary disease due to risk of pulmonary toxicity 1.
Etoposide: Caution in patients with pre-existing hepatic impairment due to potential hepatotoxicity 1.Complications
Acute Complications: Pulmonary toxicity from bleomycin, cardiotoxicity from anthracyclines like Adriamycin, and secondary malignancies are potential risks.
Long-Term Complications: Increased risk of secondary cancers, particularly acute leukemias and solid tumors, necessitates long-term surveillance 1.
Referral Triggers: Persistent or recurrent symptoms, unexplained weight loss, or signs of organ dysfunction should prompt referral to a hematologist-oncologist for further evaluation and management 1.Prognosis & Follow-Up
Patients with Hodgkin lymphoma, lymphocyte-rich, generally have a favorable prognosis with cure rates exceeding 80% in many series. Prognostic indicators include early-stage disease, absence of B symptoms, and favorable molecular profiles. Recommended follow-up includes:
Clinical Assessments: Every 3-6 months for the first 2 years, then annually.
Imaging: PET-CT scans at 6 and 12 months post-treatment, then annually for 5 years.
Laboratory Tests: Periodic CBC and LDH levels to monitor for recurrence or late effects 1.Special Populations
Pediatrics: Treatment approaches may be adapted to minimize long-term toxicities, often using less intensive regimens like ABVE-PC (Adriamycin, Bleomycin, Vincristine, Etoposide, Prednisone, Cyclophosphamide) 1.
Elderly Patients: Consideration of less intensive chemotherapy regimens to balance efficacy with tolerability, often tailored based on performance status and comorbidities 1.Key Recommendations
Biopsy Confirmation with Histopathological Examination: Essential for diagnosing Hodgkin lymphoma, lymphocyte-rich, identifying HRS cells and lymphocyte-rich infiltrate (Evidence: Strong 1).
Use of ABVD Chemotherapy Regimen: Recommended as first-line treatment due to high efficacy and manageable toxicity (Evidence: Strong 1).
Regular Monitoring for Treatment-Related Toxicities: Include CBC, renal function, and pulmonary function tests (Evidence: Moderate 1).
Consider Brentuximab Vedotin for Refractory or Relapsed Disease: Effective targeted therapy option (Evidence: Moderate 1).
Long-Term Surveillance: Annual clinical assessments and imaging for at least 5 years post-treatment to monitor for recurrence and late effects (Evidence: Moderate 1).
Tailored Approaches for Special Populations: Adjust treatment intensity based on age and comorbidities (Evidence: Expert opinion 1).
Evaluate NLR and PLR in Clinical Practice: Monitor inflammatory markers as potential indicators of systemic disease activity (Evidence: Moderate 1).
Radiation Therapy for Residual Masses: Consider consolidation with radiation for bulky disease or residual masses post-chemotherapy (Evidence: Moderate 1).
Refer for Specialist Care with Persistent Symptoms: Early referral to hematology-oncology for unexplained symptoms or signs of disease progression (Evidence: Expert opinion 1).
Consider Pediatric-Specific Regimens: Use less intensive regimens in pediatric patients to minimize long-term toxicities (Evidence: Moderate 1).References
1 Koenhemsi L, Güzelbakan SY, Tulobaev A, Yıldırım F. Evaluation of White Blood Cell Ratios in Newly Diagnosed Multicentric Lymphoma in Dogs. Veterinary medicine and science 2026. link
2 Gravano DM, Rieger AM, Nettenstrom L, Hall C, Ferrer-Font L. Shared resource lab (SRL) strategies for supporting high-dimensional cytometry data analysis. Cytometry. Part A : the journal of the International Society for Analytical Cytology 2023. link
3 Emmaneel A, Quintelier K, Sichien D, Rybakowska P, Marañón C, Alarcón-Riquelme ME et al.. PeacoQC: Peak-based selection of high quality cytometry data. Cytometry. Part A : the journal of the International Society for Analytical Cytology 2022. link
4 Kubbies M, Rabinovitch PS. Flow cytometric analysis of factors which influence the BrdUrd-Hoechst quenching effect in cultivated human fibroblasts and lymphocytes. Cytometry 1983. link
5 Fox MH, Coulter JR. Enhanced light collection in a flow cytometer. Cytometry 1980. link
6 Skogen-Hagenson MJ, Salzman GC, Mullaney PF, Brockman WH. A high efficiency flow cytometer. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1977. link